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Abstract
Background: Diverticular disease (DD) is a common condition, 
especially in Western countries. In about 80% of patients, 
colonic diverticula remain asymptomatic (diverticulosis), 
while approximately 20% of patients may develop abdominal 
symptoms (symptomatic uncomplicated diverticular disease, 
SUDD) and, eventually complications as acute diverticulitis 
(AD). The management of this condition has been improved, 
and in the last five years European countries and the USA have 
published guidelines and recommendations.
Scope: To summarize the latest evidence and clinical implication 
in treatment of DD focusing the attention either on the 
treatment of diverticulosis, SUDD and AD together with the 
primary and secondary prevention of diverticulitis.
Findings: The present review was based on the latest evidence 
in the treatment of DD in the last 10 years. In the last 5 years, six 
countries issued guidelines on DD with differences regarding 
covered topics and recommendations regarding treatments. 
At present there is a lack of rationale for drug use in patients 
with asymptomatic diverticulosis, but there are limited 
indications to suggest an increase in dietary fibre to reduce 
risk of DD. To achieve symptomatic relief in SUDD patients, 
several therapeutic strategies with fibre, probiotics, rifaximin 
and mesalazine have been proposed even if a standard 
therapeutic approach remained to be defined. Agreement 
has been reached for the management of AD, since recent 
guidelines showed that antibiotics can be used selectively, 
rather than routinely in uncomplicated AD, although use of 
antibiotics remained crucial in the management of complicated 
cases. With regard to treatment for the primary and secondary 
prevention of AD, the efficacy of rifaximin and mesalazine has 
been proposed although with discordant recommendations 
among guidelines.
Conclusion: Treatment of DD represented an important 
challenge in clinical practice, especially concerning management 
of SUDD and the primary and secondary prevention of AD.
Keywords: acute diverticulitis, diverticulosis, fibre, guidelines, 
mesalazine, probiotics, rifaximin, symptomatic uncomplicated 
diverticular disease, treatment.
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Introduction
In Western countries, colonic diverticula are significantly 
frequent, affecting up to 50–66% of individuals aged  
80 years or older [1]. The majority of individuals with colonic 
diverticula remain asymptomatic (i.e., colonic diverticulosis), 
whereas about one-fifth of subjects may develop abdominal 
symptoms, as abdominal pain, changes in bowel habits and 
bloating, a condition termed symptomatic uncomplicated 
diverticular disease (SUDD). This condition might resemble 
irritable bowel syndrome (IBS), but features of abdominal 
pain and presence of pain lasting for more than 24 hours 
might help to differentiate patients with SUDD from those 
with IBS [2–6]. About 4% of patients with colonic diverticula 
develop acute diverticulitis (AD), an inflammatory process 
that may result in complications in about 15% of patients, 
with the development of abscesses, perforation, fistula, 
obstruction or peritonitis [7]. Recurrence of diverticulitis 
after the first episode has been reported to occur in 15–30% of 
patients [8,9].
Recently, the Western scientific community has focused 
more attention to DD and, in the last 5 years, many European 
countries [10–15] and the USA [16] have published guidelines 
and recommendations, but the topics discussed were not the 
same among countries (Table 1). All cited guidelines focused 
their attention on AD, with less attention to diverticulosis and 
SUDD treatments (Table 1).
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The aim of this review is to summarize the latest evidence and 
clinical implications for the treatment of DD focusing on the 
treatment of diverticulosis, SUDD and AD together with the 
primary and secondary prevention of diverticulitis.
Methods
The present review was based on the most relevant topics 
related to the latest evidence and clinical implications in 
the treatment of DD. These include the following topics: 
(i) treatment of colonic diverticulosis; (ii) treatment of SUDD; 
(iii) treatment of AD; (iv) treatment for the primary prevention 
of AD; (v) treatment for the secondary prevention of AD. Each 
topic was dealt with according to the best evidence available, 
with particular reference to the most recent European and US 
guidelines on diverticular disease. A comprehensive search of 
the PubMed and Scopus database up to December 2017 was 
performed. Reports published in English, during the last 10 
years were considered. Colonic diverticular bleeding and the 
surgical treatment of DD were not addressed in this review.
Results
Colonic diverticulosis
Colonic diverticulosis represents an incidental finding 
in asymptomatic patients undergoing gastrointestinal 
evaluation for other indications. After 50 years of age, 
colonic diverticulosis is the most commonly reported finding 
reported on colonoscopy usually performed for colon cancer 
screening [17]. One of the most frequently asked questions 
is whether these asymptomatic patients should be treated. 
Polish [13] and Italian [14,15] guidelines addressed the issue of 
pharmacological treatment of diverticulosis, suggesting that 
no rationale for treatment or monitoring asymptomatic colonic 
diverticulosis subsist (Table 1). As for dietetic counselling, there 
are limited indications to suggest an increase in dietary fibre 
to reduce the risk of DD in this setting [10,14,15] (see paragraph 
‘Treatment for the primary prevention of acute diverticulitis’).
Symptomatic uncomplicated 
diverticular disease
SUDD represents a ‘grey’ clinical condition characterized by 
recurrent abdominal symptoms such as recurrent abdominal pain, 
bloating and changes in bowel habits attributed to diverticula in 
the absence of macroscopical alterations other than diverticula. 
Abdominal complaints observed in SUDD may be similar from 
those of IBS, but some abdominal pain features would be helpful 
to differentiate these two disorders [2–6,18]. A key difference 
between pain associated with SUDD and IBS is the localisation of 
the pain: IBS patients typically complained of diffuse/generalised 
pain, whereas SUDD patients have a pain often localised in 
left iliac fossa. During pain, IBS patients may experience either 
diarrhoea or constipation, while in DD, diarrhoea is slightly more 
frequent. Another diagnostic feature in IBS is the relief of pain by 
defecation or flatulence, while SUDD patients did not present this 
picture. In addition, SUDD presented more frequently a long-
lasting pain, lasting more than 24 hours [2–6,18].
International guidelines partially address the definition 
[13,14,15] and treatment [10,12–15] of SUDD (Table 1). The main 
purpose in the management of SUDD is the relief of abdominal 
symptoms. Even if a standard therapeutic approach still 
remained to be defined, several dietary and pharmacologic 
strategies have been proposed in this condition. DD is a 
complex, multifactorial disorder, in which the gut microbiota 
could play a pathogenetic key role. In fact, Barbara and 
colleagues recently reported that patients with DD showed 
depletion of microbiota members with anti-inflammatory 
properties, including Clostridium cluster IV, Clostridium cluster 
IX, Fusobacterium and Lactobacillaceae, with microbiota 
Table 1. Comparison among European and US guidelines: covered topics.
Andersen 
et al. [10], 
Denmark
Andeweg 
et al. [11], 
Holland
Kruis  
et al. [12], 
Germany
Pietrzak 
et al. [13], 
Poland
Cuomo  
et al. [14], 
Italy
Binda  
et al. [15], 
Italy
Stollman  
et al. [16],  
USA
Diverticulosis Only 
definition
Only 
definition
Only 
definition
√ √ √
Symptomatic uncomplicated 
diverticular disease
√ √ √
Acute diverticulitis √ √ √ √ √ √ √
Treatment of diverticulosis √ √ √
Treatment for symptomatic 
uncomplicated diverticular disease
√ √ √ √ √
Treatment for acute diverticulitis √ √ √ √ √ √ √
Prevention of acute diverticulitis √ √ √ √ √ √
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however, several limitations – largely arising from the nature 
of the included studies – impair the results of this systematic 
review [28]. As a consequence, available data do not allow 
conclusions to be made. Based on these data, Italian guidelines 
argued that there is insufficient evidence that probiotics are 
effective in reducing symptoms [14].
Rifaximin
Rifaximin is a poorly absorbable oral antibiotic for the treatment 
of several gastrointestinal diseases (i.e., acute bacterial 
diarrhoea, portal systemic encephalopathy). This drug exerts its 
gastrointestinal activity because of its peculiar pharmacological 
activities, viz.: non-systemic absorption, thus high faecal 
concentration and a broad spectrum of antimicrobial activity [29]. 
Furthermore, rifaximin acts through different mechanisms: 
(i) inhibition of bacterial growth; (ii) increase of resistance to 
bacterial infection; (iii) modulatory effect of some bacterial 
species, such as Lactobacillus spp and Bifidobacterium spp, 
leading to the so-called eubiotic effect; (iv) modulation of 
bacterial metabolism; (v) anti-inflammatory activity [29–31]. For 
these reasons, rifaximin is often used in European countries for 
symptomatic relief in SUDD patients and for the prevention of 
AD. Use of rifaximin in DD has been recently summarised in two 
systematic reviews [32,33], one of which is a meta-analysis [32].  
The meta-analysis found that 64% of patients treated with 
rifaximin plus fibre supplements were symptom-free at one-
year follow-up compared with 34.9% of patients treated with 
fibre alone. The pooled rate difference for symptom relief was 
29.0% (rifaximin vs control; 95% CI: 24.5–33.6; p<0.0001; number 
needed to treat [NNT]=3) [32]. A non-interventional study, in an 
outpatient setting, evaluated the efficacy of rifaximin (400 mg 
b.i.d. for 7–10 days) for 3 months. The authors confirmed the 
beneficial effect of rifaximin on global gastrointestinal symptoms 
and showed a good safety profile of cyclic administration [34]. 
A more recent ‘real-life’ study conducted in an outpatient 
setting, evaluated the effect of the same therapeutic regimen 
in 142 SUDD patients: after 3 months, a significant reduction in 
symptoms was observed, and severity score symptoms reduced 
from 1.7±0.7 to 0.3±0.1 (p<0.001) [35].
Danish [10], Polish [13] and Italian [14,15] concur that cyclic 
rifaximin plus fibre supplementation should be used for SUDD 
patients for symptom relief. Furthermore, the position paper 
of the Italian Society of Gastroenterology on use of rifaximin 
in DD, supported its use together with fibre in SUDD, with 
a moderate grade of evidence [31]. However, the efficacy of 
rifaximin in SUDD needed to be further investigated in larger 
RCT placebo-controlled, in order to assess the best therapeutic 
dosage, the modality of administration (continue vs cyclic) and 
its efficacy alone or in association with probiotics.
Mesalazine
5-aminosalicylic acid (mesalazine) is an anti-inflammatory 
drug primarily used as a first-line therapy for patients with 
changes being related with mucosal immune activation [19]. On 
these basis, treatments having gut microbiota as therapeutic 
targets, such as fibres, probiotics or rifaximin have been 
proposed in SUDD [20].
Fibre
Although dietary and supplementary fibre have been proposed 
for the symptomatic relief in SUDD patients, the therapeutic 
benefit is not yet fully understood. In SUDD patients, fibres might 
act through: (i) conferring benefits by increasing faecal mass and 
promoting the regularity of bowel movements; (ii) capability to 
act as prebiotics in the colon, by favouring health-promoting 
species of the intestinal microbiota, especially bifidobacteria 
and lactobacilli [21]. The gut microbiota, indeed, shifts rapidly in 
response to dietary changes, particularly with fibre intake [22]. 
However, evidence for a therapeutic benefit of a high-fibre diet in 
the treatment of DD is poor. Five years ago, a systematic review 
assessed whether a high-fibre diet can improve symptoms or 
prevent complications of DD. Few studies (three randomised 
control trials [RCTs] and one case–control study) were identified, 
and the authors concluded that high-quality evidence for a high-
fibre diet in the treatment of DD is lacking [23]. A more recent 
systematic review aimed to update the evidences on the efficacy 
of fibre treatment, both dietary and supplemental, in terms of 
a reduction in symptoms and the prevention of AD in SUDD 
patients [24]. Nineteen studies were included, nine with dietary 
fibre and ten with supplemental fibre, with a high heterogeneity 
concerning the quantity and quality of fibres employed. Authors 
concluded that, even single low-quality studies suggest that 
fibres, both dietary and supplemental, could be beneficial in the 
treatment of SUDD, the presence of substantial methodological 
limitations, the heterogeneity of therapeutic regimens 
employed, and the lack of ad hoc designed studies, do not 
permit a summary of the outcome measures. On the basis of 
these data, fibre supplements are suggested in Danish [10] and 
Polish [13] guidelines, whereas Italian guidelines argue that fibre 
supplementation alone provides controversial results in terms of 
symptom relief [14,15].
Probiotics
Probiotics may modify the gut microbial balance leading to 
health benefits due to their anti-inflammatory effects and 
capability to enhance anti-infection defences by maintaining 
an adequate bacterial colonization in the gastrointestinal tract 
and by inhibiting colonic bacterial overgrowth and metabolism 
of pathogens [25–27]. A recent systematic review aimed to 
summarize data on the efficacy of probiotics in DD in terms of 
remission of abdominal symptoms and prevention of AD [28]. 
Eleven studies (two were double-blind, randomized, placebo-
controlled; five were open, randomized; four were non-
randomized open studies) were selected. Authors concluded 
that even the efficacy of probiotics reported in the single-
controlled studies seemed to show a trend toward a positive 
clinical response on abdominal symptoms or their recurrence; 
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patients do not present all these symptoms at the same 
time [43]. Furthermore, patients might have change in bowel 
habits, nausea, vomiting, urinary symptoms and elevated 
inflammatory markers. Contrast-enhanced computerised 
tomography (CT) should be considered as the first-line colonic 
examination since it offers a more comprehensive evaluation 
of uncomplicated and complicated forms [14,15]. In fact, the 
severity of diverticulitis is graded with the use of modified 
Hinchey’s Criteria, based on CT imaging and on preoperative 
findings [44]. An important role in AD diagnosis is also 
provided by abdominal ultrasound (US), which in the hands 
of experienced investigators can be used as a sensitive and 
specific diagnostic technique [11,12,14,15]. A multicentre study 
evaluating the accuracy of US compared with CT in unselected 
patients referred for acute abdominal pain to the emergency 
department, showed that CT have higher sensitivity compared 
to US in detecting AD (81 vs 61%; p=0.048) [45]. Presently, a 
strategy providing CT after negative or inconclusive US has 
been proposed [11,14,15].
The majority of AD episodes are uncomplicated, with 
about 15% presenting complications as abscesses, fistulas, 
obstructions and perforations; even if a recurrence of AD has 
been reported in 15–30% of patients, generally the first episode 
is the most severe [8,9]. In a retrospective cohort study it has 
been showed that, during a follow-up period of 8.9 years, 
recurrence of AD appeared in 13.3% of patients and only 
3.9% had a second recurrence. In this cohort, non-operative 
treatment was used in 80.6% of patients, whereas emergency 
colectomy was performed in 19.4% [9]. During follow-up, 
elective colectomy was performed in 7.3% of patients, with all 
re-recurrences were treated non-operatively [9].
Some lifestyle factors such as smoking, physical activity, dietary 
habits and especially fibre consumption have been associated 
to the development of diverticulitis [46].
Until 10 years ago, antibiotics were considered mandatory in 
the treatment of AD, even in mild episodes. This practice was 
based on the belief that diverticulitis was due to obstruction of 
a diverticulum leading to mucosal abrasions, microperforation 
and bacterial translocation [42]. However, this concept has been 
changed with newer hypotheses highlighting that AD may 
be an inflammatory rather than an infectious condition [47]. 
In fact, prospective randomized [48,49], case–control [50] and 
retrospective cohort study [51] shown no benefit for the use of 
antibiotics in the treatment of uncomplicated AD, suggesting 
that its use should be reserved for the treatment of complicated 
disease. The most recent RCT, was a multicentric observational 
study compared with antibiotic treatment (amoxicillin plus 
clavulanic acid 1.2g four times daily intravenously (i.v.) for at least 
48 h, after which the route was switched to oral administration 
of 625 mg three times daily) for a first episode of CT-proven 
uncomplicated AD [49]. Regarding the primary endpoint, no 
differences about the median time to recovery were found: 
14 days (6–35 days) for the observational and 12 days (7–30 
days) for the antibiotic treatment strategy with a hazard ratio 
inflammatory bowel disease. Its anti-inflammatory effect is not 
fully understood, but several mechanisms are likely involved:  
(i) reduction in synthesis of prostaglandins and pro-
inflammatory cytokines; (ii) inhibition of the chemotaxis of 
neutrophils and inhibition of activation of nuclear factor 
kB transcription family (important for pro-inflammatory 
cytokines production); (iii) activation of nuclear receptor 
that downregulate inflammation; (iv) change in luminal pH 
(favouring growth of beneficial colonic bacteria) [36–38].
In SUDD, the rationale for the use of mesalazine is based on the 
recognition of inflammation as a therapeutic target [39].  
Regarding the efficacy of mesalazine in SUDD, only two 
studies are double-blind and placebo controlled. Kruis and 
colleagues investigated the efficacy of mesalazine in a double-
blind, placebo-controlled, multicentre, 6-week trial, where 
patients were randomized to mesalazine 3 g/day (Salofalk® 
granules, which differ from other mesalazine by combining 
both delayed and extended-release mechanisms) or placebo, 
in uncomplicated DD [40]. Regarding the primary endpoint, the 
change in lower abdominal pain with mesalazine compared 
with placebo was not different in the intent-to-treat (ITT) 
population (p=0.374), but better results were reached in the 
per-protocol (PP) population (p=0.053). Post hoc adjustment for 
confounding factors resulted significant in the PP population 
(p=0.005) [40]. In Italy, a multicentre, double-blind, placebo-
controlled study investigated the efficacy of cyclic treatment 
(10 days/month for one year) with mesalazine 1.6 g/day with 
or without Lactobacillus casei subspecies DG 24 billion/day, in 
maintaining clinical remission of SUDD after a first episode [41]. 
Recurrence of SUDD occurred in 0% of patients treated with 
mesalazine and probiotics (group LM), in 13.7% of patients 
treated with mesalazine (group M), in 14.5% of patients 
treated with probiotics (group L) and in 46.0% of patients treated 
with placebo (group P) (p<0.001 for group LM, L and L vs P) [41].
Furthermore, the efficacy of mesalazine in SUDD has been 
evaluated in several open randomized trials, which results 
are summarised in recent reviews [32,38]. Even if some 
positive results have been found, the data presented different 
endpoints, different dosage and modality of treatments 
(continue vs cyclic) appearing heterogeneous, and no valid 
conclusion can be drawn. These discrepancies have led to 
different recommendations in Western guidelines, since 
Italian guidelines contend that there is no clear evidence that 
mesalazine alone is effective in reducing symptoms [14,15], 
whereas German guidelines [12] state that this condition can 
be treated with mesalazine. Further larger placebo-controlled 
RCTs are needed to establish if mesalazine represents a useful 
therapy in this condition and its therapeutic regimen.
Treatment of acute diverticulitis
AD is an inflammatory condition affecting at least one colonic 
diverticula, often associated with pericolonic inflammation [42].  
Patients with AD usually complain of abdominal pain in the 
left lower quadrant, fever and leukocytosis, even if some 
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antibiotics (Table 2). Antibiotics that are more often used in AD 
include: ciprofloxacin (500 mg twice daily orally or 200 twice 
daily i.v.) combined with metronidazole (250–500 mg three 
times daily orally or 500 mg three times daily i.v.); amoxicillin-
clavulanic acid (650 mg–1 g twice daily orally or 1, 2, 3, 4 times 
per day i.v.) [13]. Also clindamycin or metronidazole combined 
with trimethoprim/sulfamethoxazole or gentamicin, are used 
[13]. Biondo and colleagues evaluated 92 papers in a systematic 
review, concluding that patients with severe AD without need 
of emergency surgery, should be treated with hospitalisation, 
parenteral fluids and a single intravenous antibiotic active 
against aerobic and anaerobic bacteria [54].
Treatment for the primary 
prevention of acute diverticulitis
Treatment for the primary prevention of AD is partially covered 
by recent guidelines, because only Polish [13] and Italian [14,15] 
guidelines deal with this topic (Table 2). Here, we summarised 
the most recent evidence about use of fibre, rifaximin and 
mesalazine in the primary prevention of AD.
Fibre
Available data suggest that people with a higher intake of 
dietary fibre than a lower intake have a lower risk of DD.  
(HR) for recovery of 0.91 (lower limit of one-sided 95% CI: 0.78; 
p=0.151). The same occurred for secondary endpoints – that 
is, no significant differences found: complicated diverticulitis 
(p=0.377), recurrent diverticulitis (p=0.494), sigmoid resection 
(p=0.323), readmission (p= 0.148), adverse events (p=0.221) 
and mortality (p=0.432) [49]. Also, a Cochrane review evaluating 
the antibiotic use in uncomplicated AD, found no significant 
difference between antibiotics compared with no antibiotics 
in the treatment of uncomplicated diverticulitis [52]. These 
findings supported the most recent European and US guidelines 
that suggested nonroutine use of antibiotics in patients with 
uncomplicated AD (Table 2). Use of antibiotics in uncomplicated 
AD should be made individually, and with indications for possible 
cases of severe infection or sepsis, severe comorbidities or in 
immunosuppressed patients [10–16].
The need of hospitalization has been also revised, since 
the safety of outpatient management of uncomplicated 
AD is emerging: a recent systematic review updating the 
evidence about the outpatient treatment of uncomplicated 
AD, concluded that this approach is safe, effective and 
economically efficient [53].
The management of complicated AD depends on its severity 
and complexity, and if it requires hospitalization, bowel rest 
and surgery in selected cases. Antibiotic therapy is part of the 
management of complicated diverticulitis and recent guidelines 
are in accordance at recommending broad-spectrum  
Table 2. Recommended medical treatment of acute diverticulitis: comparison among European and US guidelines.
Andersen  
et al. [10],  
Denmark
Andeweg  
et al. [11], 
Holland
Kruis  
et al. [12], 
Germany
Pietrzak  
et al. [13],  
Poland
Cuomo  
et al. [14],  
Italy
Binda  
et al. [15],  
Italy
Stollman  
et al. [16],  
USA
Treatment of acute 
uncomplicated diverticulitis
Not 
routine 
use of 
antibiotics
Not routine 
use of 
antibiotics
Not routine 
use of 
antibiotics
Not 
routine 
use of 
antibiotics
Not 
routine 
use of 
antibiotics
Not 
routine 
use of 
antibiotics
Not routine 
use of 
antibiotics
Treatment of acute 
complicated diverticulitis
Antibiotics Antibiotics Antibiotics Antibiotics Antibiotics Antibiotics NR
Primary prevention of acute 
diverticulitis 
NR NR NR Rifaximin+
fibre
Rifaximin+
fibre
Rifaximin+
fibre
NR
Secondary prevention of 
acute diverticulitis
NR Rifaximin or
Rifaximin+ 
Mesalazine
or
Mesalazine±
Rifaximin or
probiotics
Neither 
rifaximin or 
mesalazine or 
probiotics are 
recommended
Rifaximin+
fibre
Rifaximin+
fibre
Rifaximin+
fibre
Neither 
rifaximin or 
mesalazine or 
probiotics are 
recommended
Antibiotics: broad-spectrum antibiotics; NR: not reported.
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prevention of AD as secondary endpoint [41]. In their study, 
mesalazine was more effective than placebo in preventing 
AD, since diverticulitis occurred in six cases of patients treated 
with placebo, in one of patients treated with probiotics, but 
no patients treated with mesalazine developed AD (p=0.003). 
Furthermore, as summarised by Maconi and colleagues [33],  
four open trials evaluated the efficacy of mesalazine, 
balsalazide, alone or in combination with probiotics, and 
probiotics alone in prevention of AD [59–62]. Considering 
together these four studies, 350 patients were included, 
reporting seven episodes of AD per year (yearly incidence 
rate=2%), and no significant difference among treatments 
were found [33].
More studies are needed to assess the efficacy of mesalazine 
alone in preventing occurrence of AD. At present, there is no 
clear evidence that mesalazine reduces episodes of AD in SUDD 
patients as per Italian guidelines [14].
Treatment for the secondary 
prevention of acute diverticulitis
Treatment for the secondary prevention of AD is discussed 
in almost all recent guidelines, although with discordant 
recommendations (Table 2). We now summarize the most 
recent evidence about use of rifaximin and mesalazine in the 
secondary prevention of AD.
Rifaximin
Several randomized trials evaluated the efficacy of rifaximin 
in secondary prevention of AD as summarised in a recent 
systematic review [33]. The most recent by Lanas and 
colleagues evaluated the efficacy of 1-year intermittent 
rifaximin (400 mg twice daily 7 days a month) plus fibre 
(Plantago ovata 3.5 g twice daily) in a multicentre open RCT 
to prevent AD recurrence [63]. After randomization, this study 
was switched from evidence-gathering to proof-of-concept 
because the recruitment rate did not reach the minimum 
anticipated. In this study, rifaximin was more effective 
compared to fibre alone in the secondary prevention of AD, 
because its recurrence occurred in 10.4% compared with 19.3% 
of patients, respectively (p=0.033). A small open trial by Tursi 
and colleagues compared rifaximin 800 mg/day for 10 days 
a month compared with mesalazine 1.6 g/day for 24 months, 
showing that 25 and 5% of patients, respectively, have a 
recurrence of diverticulitis (p=0.002) [64].
These weak data have led to different recommendations 
in Western guidelines with European guidelines advising 
that rifaximin seems to reduce the risk of recurrence of 
diverticulitis [11,13–15], whereas German [12] and US guidelines 
[16] suggest against the use of rifaximin. Available evidences 
are based on only a few studies with methodological 
limitations and heterogeneity of therapeutic regimens. 
Further placebo-controlled RCTs are needed to determine 
A large prospective cohort study examined the associations 
between a vegetarian diet and dietary fibre intake with risk of 
DD. After a mean follow-up time of 11.6 years, vegetarians had 
a 31% lower risk (relative risk [RR] 0.69, 95% CI: 0.55–0.86) of DD 
compared with meat eaters. DD risk is inversely associated with 
dietary fibre consumption; participants consuming the highest 
quantity of fibre had a 41% lower risk of DD (0.59, 0.46–0.78; 
p<0.001 trend) compared with those consuming less fibre [55]. 
A more recent prospective study conducted on a cohort of 
middle-aged women confirmed this observation, reporting 
that the association with DD risk varied by the source of fibre, 
the reduced risk being strongest for cereal and fruit fibre [56]. 
Based on these data, recent European guidelines support the 
use of a high-fibre diet for the prevention of acute diverticulitis 
[11–15].
Rifaximin
Bianchi and colleagues, in a meta-analysis, summarised the 
results of four RCTs (only one of which was double-blind) 
that have evaluated the efficacy of rifaximin with fibre 
supplementation to prevent AD in patients with colonic DD. 
They found that the pooled RD=rate difference in the treatment 
group was –2% (95% CI: –3.4 to –0.6; p=0.0057; NNT=50) [32]. 
However, the only double-blind, placebo-controlled trial 
assessing the efficacy of rifaximin (400 mg twice daily for 7 
days a month plus glucomannan 2 g/day) compared with 
glucomannan alone, found that both treatments showed 
the same effectiveness, since AD occurred in 2.4% of both 
group [57]. Maconi and colleagues evaluated data from 
placebo-controlled and unblended trials showing that AD 
was less frequent in patients treated with rifaximin plus fibre 
supplementation (1.1%) in comparison to fibre alone (2.9%) 
(p=0.012). Based on these data, the NNT to prevent an episode 
of AD in 1 year was 57 [33]. A recent retrospective study 
evaluated the efficacy of rifaximin (400 mg twice daily for 7 
days a month, every 3 months) for 1 year in preventing AD 
[58]. Authors observed that AD rate between the 6th and 12th 
month was lower in the rifaximin group (p=0.0001), with a 
further improvement of quality of life [58]. Although with a low 
grade of evidence, the position paper of the Italian Society of 
Gastroenterology, suggested that rifaximin when administrated 
with fibre reduces the occurrence of diverticulitis (primary 
prevention) in patients with SUDD [31].
Finally, some evidence suggests that rifaximin may reduce the 
risk of occurrence of AD when associated with fibre intake, 
as advised in Polish [13] and Italian [14,15] guidelines, even 
though there is a high NNT and only a low number of RCT 
available.
Mesalazine
Tursi and colleagues, in a placebo-controlled trial designed 
to evaluate the effectiveness of mesalazine and/or probiotics 
in maintaining remission in SUDD, assessed the efficacy in 
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74.4% (p=0.226) and 46, 52 and 58% (p=0.86) in SAG-37  
and SAG-51, respectively, over 48 weeks [67]. Also a recent 
Cochrane review (not including Kruis and colleagues’ study), 
concluded that the effects of mesalazine on recurrence of 
diverticulitis are uncertain owing to the small number of 
heterogeneous trials available [68].
Based on the available evidence, guidelines showed some 
discrepancies, since Dutch [11] guidelines suggested its use, 
whereas German [12], Polish [13], Italian [14] and US guidelines 
[16] did not recommend use of mesalazine in the secondary 
prevention of acute diverticulitis.
Discussion
Data emerging from this review suggests the potential 
use of fibre, probiotics, rifaximin and mesalazine and their 
possible combination in treatment of DD. In the last 5 years, 
six countries have issued guidelines that differ with regard to 
topics covered and recommendations regarding treatment. 
Recent evidence regarding the treatment of SUDD and the 
primary and secondary prevention of AD are conflicting, 
and often based on uncontrolled trials. However, guidelines 
agreement has been reached with regard to the management 
of AD, since recent strong data showed that antibiotics can be 
used selectively, rather than routinely, in uncomplicated AD, 
though use of antibiotics remains crucial in the management 
of complicated cases.
This review suggests the need of robust well-designed 
placebo-controlled RCTs that take into consideration of the 
clinical history of patients (i.e., asymptomatic vs symptomatic/
with or without previous episode of AD) in order to achieve 
clearer evidence for each patient’s DD categories and to 
optimize clinical practice.
the real benefit of rifaximin for the secondary prevention of 
diverticulitis.
Mesalazine
Recently, the efficacy of mesalazine in the secondary 
prevention of AD has been evaluated in large RCTs. Stollman 
and colleagues evaluated – in a 1-year double-blind, 
randomized, placebo-controlled study – the efficacy of 
mesalazine or mesalazine+Bifidobacterium infantis 35624, in 
the prevention of AD [65]. In this trial, mesalazine alone, or in 
combination with probiotics, did not prevent recurrence; the 
proportion of diverticulitis was comparable between the two 
groups [65]. Raskin and colleagues investigated the efficacy 
of mesalazine in preventing recurrence of diverticulitis in two 
identical but separate Phase III, randomized, double-blind, 
placebo-controlled, multicenter trials, involving 590 (PREVENT1) 
and 592 (PREVENT2) patients, respectively [66]. Patients were 
randomized to receive mesalazine (1.2, 2.4 or 4.8 g) or placebo 
once daily for 104 weeks. Authors reported that, among 
patients in PREVENT1, 53–63% did not have disease recurrence, 
compared with 65% of those given placebo, whereas among 
patients in PREVENT2, 59–69% of patients did not have disease 
recurrence, compared with 68% of those given placebo; thus 
without differences between groups [66]. More recently two 
Phase III, randomised, placebo-controlled, double-blind 
multicentre trials (SAG-37 and SAG-51) investigated the efficacy 
of mesalazine granules in the prevention of recurrence [67]. 
Patients were randomised to receive either 3 g of mesalazine 
once daily or placebo (SAG-37, n=345) or to receive either 1.5 g 
mesalazine once daily, 3 g once daily or placebo for 96 weeks 
(SAG-51, n=330). Mesalazine did not increase the proportion 
of recurrence-free patients compared to placebo, being 
proportion of recurrence-free patients 67.9% compared with 
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